XML 34 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue by Product
9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Revenue by Product
Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total revenues by these products: 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Revenues by Product:
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
Bloxiverz
 
$
1,466

 
$
3,656

 
$
6,392

 
$
16,691

Vazculep
 
8,786

 
8,759

 
27,669

 
33,097

Akovaz
 
4,208

 
5,991

 
13,946

 
28,083

Other
 
(231
)
 
1,420

 
213

 
4,232

Total product sales
 
14,229

 
19,826

 
48,220

 
82,103

License revenue
 

 

 

 
246

Total revenues
 
$
14,229

 
$
19,826

 
$
48,220

 
$
82,349